SEC Company Response from Viridian Therapeutics, Inc.\DE (VRDN) (CIK 0001590750) (VRDN) — Nov 15, 2021
Viridian Therapeutics, Inc.\DE (VRDN) (CIK 0001590750)
Date: Nov. 15, 2021 · CIK: 0001590750 · Accession: 0001193125-21-329814
AI Filing Summary & Sentiment
File numbers found in text: 333-260859
Letter
Viridian Therapeutics, Inc.
221 Crescent Street, Suite 401
Waltham, MA 02453
(617) 272-4600
November 15, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Re: Viridian Therapeutics, Inc.
Registration Statement on Form S-3 (File No. 333-260859)
To Whom it May Concern:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Viridian Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above referenced registration statement (the “Registration Statement”) be accelerated to November 17, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Ryan A. Murr at (415) 393-8373.
Very truly yours,
Viridian Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Viridian Therapeutics, Inc. 221 Crescent Street, Suite 401 Waltham, MA 02453 (617) 272-4600 November 15, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Re: Viridian Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-260859) To Whom it May Concern: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Viridian Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above referenced registration statement (the “Registration Statement”) be accelerated to November 17, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Ryan A. Murr at (415) 393-8373. Very truly yours, Viridian Therapeutics, Inc. By: /s/ Jonathan Violin, Ph.D. Name: Jonathan Violin, Ph.D. Title: President and Chief Executive Officer cc: Ryan A. Murr, Gibson, Dunn & Crutcher LLP Branden C. Berns, Gibson, Dunn & Crutcher LLP